How do I buy Spero Therapeutics, Inc. Common Stock (SPRO) stock?

Buying Spero Therapeutics, Inc. Common Stock (SPRO) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "SPRO", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy SPRO by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for SPRO on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Spero Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Spero Therapeutics, Inc. Common Stock (SPRO) pay dividends?

At the moment, Spero Therapeutics, Inc. Common Stock (SPRO) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track SPRO's performance via the price chart in the Gotrade app.

Is buying SPRO on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy SPRO?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if SPRO is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price Today & Analysis

% positive news of 6 articles

published over the past 14 days

Latest news

MarketBeat

Spero Therapeutics Q2 Earnings Call Highlights

NeutralSPROAugust 13, 2026

MarketBeatNeutral

Spero Therapeutics Q2 Earnings Call Highlights

SPRO

Reuters

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

NeutralSPROJuly 14, 2026

ReutersNeutral

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

SPRO

Zacks Investment Research

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

NeutralSPROJune 18, 2026

Zacks Investment ResearchNeutral

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

SPRO

Business Wire

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

NeutralSPROJune 17, 2026

Business WireNeutral

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

SPRO

Zacks Investment Research

About Spero Therapeutics, Inc. Common Stock

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

SectorHealthcare

IndustryBiotechnology

Employees25

CEOMs. Esther P. Rajavelu

IPO DateNov 2, 2017

HeadquartersCambridge, MA

Key Executives

Name	Title	Year Born
Ms. Esther P. Rajavelu	CEO, President, CFO, Chief Business Officer, Treasurer & Director	1979
Mr. Timothy Keutzer	Chief Operating Officer	1968
Mr. John Raymond	Senior Vice President of Finance & Business Operations	—
Dr. Debra Jeske Zack M.D., Ph.D.	Chief Medical Officer	1957
Ms. Sheila Finan	Senior VP & Controller	—

Fundamentals

Valuation

Market cap$71.63M

Price-to-sales ratio1.55

Price-to-book value1.65

Price-earnings ratio9.90

Return on Equity36.00%

Return on Sales25.00%

Return on Assets25.00%

PEG ratio0.00

Earnings Per Share

Earnings Per Share$0.14

Income Statement

Average volume740,265

EBITDA$15.50M

1 year high (52w)$3.08

1 year low (52w)$1.08

Dividend

Ex dividend dateN/A

Dividend amount$0.00

Dividend yield0.00%

Last payment dateN/A

Dividend yield (TTM)N/A

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsStrong Buy5 Indicators

Moving AveragesStrong Sell12 Indicators

What the experts say

1 Wall Street Analyst Ratings

BUY

100% Buy

0% Hold

0% Sell

Target price

$6.00

Est return

391.80%

HC Wainwright & Co.

Raghuram Selvaraju

Buy

Target price

$6.00

Est return

404.20%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026					+11.0	-21.9	-47.3	+6.1	+2.5

Spero Therapeutics, Inc. Common Stock (SPRO) Stock

Fundamentals

Recent news

Spero Therapeutics Q2 Earnings Call Highlights

Spero Therapeutics Q2 Earnings Call Highlights

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Spero Therapeutics Q2 Earnings Call Highlights

Spero Therapeutics Q2 Earnings Call Highlights

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

New Strong Buy Stocks for November 15th

New Strong Buy Stocks for November 15th

Spero's stock jumps 188% after GSK licenses experimental antibiotic

Spero's stock jumps 188% after GSK licenses experimental antibiotic

About Spero Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade